Because CD1d is expressed in acute lymphoblastic leukemia (ALL), AML, B-cell chronic lymphoblastic leukemia (CLL), juvenile myelomonocytic leukemia, and non-Hodgkin lymphoma (NHL)61, NKT cell therapy may be applied to treat CD1d-expressing hematologic malignancies. Here, CD1D is linked to acute myeloid leukemia.